Henry Schein (HSIC) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $1.27
- Estimate
- $1.24
- Surprise
- +2.5%
- Revenue (period 2026-06-27)
- $3.46B
- Score at report (before → after)
- 5.1 → 5.1/10
Revenue source: xbrl.
How the report landed
Henry Schein (HSIC) beat the $1.24 estimate with diluted EPS of $1.27 — a modest 2.5% upside surprise. TrendMatrix's engine moved from Hold (5.1/10) to Buy (Wait) at 5.1/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates HSIC Sell at 5.2/10.
4 of the last 4 quarters beat the estimate; this quarter's +2.5% surprise compares with a +5.6% four-quarter average. Next scheduled report: 2026-11-03.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (4/4)
What argues against it
- Analyst target reached - limited upside remaining
- Near 52-week high (4.1% away)
- V7 low-quality RISK_OFF penalty: -0.5 (Q=4.1)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $88.36
- Price target
- $88.37
- Stop
- $85.06
- Upside to target
- 0.0%
The stock trades at 25.8× trailing but 14.7× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-09-14 — shown for context, not personalized investment advice.
HSIC at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Distribution
- Market cap
- $9.85B
- P/E (fwd)
- 14.7
- P/E (ttm)
- 25.8
- 52-week range
- $61.95–$92.18
- Off 52-week high
- 4.1%
- RSI (14)
- 49
- Volume vs avg
- 0.79×
- Score today
- 5.2/10